Selected publications
-
Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma.
Clinical Cancer Research.
2018
Academic Article
GET IT
Times cited: 18 -
Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma.
Journal of Clinical Oncology.
2017
Academic Article
GET IT
Times cited: 122 -
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
European Urology.
2017
Academic Article
GET IT
Times cited: 74 -
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
European Urology.
2017
Academic Article
GET IT
Times cited: 71 -
Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy.
New England Journal of Medicine.
2016
Academic Article
GET IT
Times cited: 260 -
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
The Lancet Oncology.
2016
Academic Article
GET IT
Times cited: 357 -
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
British Journal of Cancer.
2015
Academic Article
GET IT
Times cited: 57 -
Cabozantinib versus everolimus in advanced renal-cell carcinoma.
New England Journal of Medicine.
2015
Academic Article
GET IT
Times cited: 531 -
Nivolumab versus everolimus in advanced renal-cell carcinoma.
New England Journal of Medicine.
2015
Academic Article
GET IT
Times cited: 2259